Dajun Yang, Ph.D., Chairman and CEO of Ascentage Pharma, has dedicated over 30 years to the research in oncology, the apoptotic pathway, as well as the R&D of innovative drugs. Since co-founding Ascentage Pharma in 2009, he made major breakthroughs in drug development and advanced multiple drug candidates with global first-/best-in-class potentials into clinical development in China, US, Australia and Europe. Under his leadership, olverembatinib, the first and only China-approved 3rd-generation BCR-ABL inhibitor, was launched and included into the NRDL, thus filling an urgent treatment gap in China.

Dr. Yang has led nearly 10 National Science & Technology Major Projects including the National High-tech R&D Program (863 Program) and “Major New Drug Development” projects. Being highly recognized for his work, Dr. Yang serves a range of positions outside his primary responsibilities, including professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center, deputy director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association, and part-time researcher in Pharmaceutical Innovations at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. In addition, Dr. Yang has served as the 8th president (2005-2006) of the Chinese Biopharmaceutical Association (CBA), USA. He and his team, widely respected in field of novel drug development, have received a series of high profile recognitions and prominent awards, including the Team for Major Innovations designations by both Suzhou municipality and Jiangsu province; the first ever Award for Teams Pioneering Innovations in Jiangsu province; the 2022 Team of Excellence in Science and Technology of Suzhou; the Tan Jiazhen Life Science Industrialization Award; Top 10 Business Leaders in the Pharmaceutical Industry, by the 14th Health China Forum organized by the People’s Daily; and the Dushu Lake Cup Award for Most Innovative Figure of Drug R&D.

Dr. Shaomeng WANG, Ph.D., is the co-founder of Ascentage Pharma and has been appointed as its chairman of the Scientific Advisory Board since 2010. Dr. Wang joined the University of Michigan in July 2001 as a tenured faculty and is currently a Warner-Lambert/Parke Davis Professor in Medicine at University of Michigan, Ann Arbor, where he also serves as the co-director of the experimental therapeutics program at the University of Michigan Comprehensive Cancer Center (the Rogel Cancer Center) and director of the Michigan Center for Therapeutic Innovation. Dr. Wang was also appointed as the editor-in-chief of the Journal of Medicinal Chemistry since 2011, and was re-appointed to the same role in 2015.

Dr. Wang obtained his Bachelor’s degree in Chemistry from Peking University in July 1986. He received his Ph.D. degree from Case Western Reserve University in Chemistry in the United States in January 1993.

Dr. Simon Dazhong LU, Ph.D., MBA, has more than 18 years of experience in the investment and consulting business. He is a Managing Director of SIDC Fund Management Company Ltd., a China-based private equity fund manager. From January 2008 to July 2009, Dr. Lu served as the Managing Director and a member of the investment committee of CEL Partners, a private equity firm. From September 2002 to December 2007, he was a partner of Shanghai Newmargin Ventures, a venture capital management company. Dr. Lu has also served as a securities analyst at China International Capital Corporation Limited, and as a financial analyst at Scotiabank in Toronto, Canada. Early in his career, he worked as an auditor and audit and business consulting supervisor at Arthur Andersen in Shanghai and Chicago. Dr. Lu graduated with a Bachelor of Economics from Nankai University, his Master of Business Administration from McGill University in Canada, and Ph.D. in Economics degree from Nankai University.

Mr. Wei REN has over 15 years of legal experience covering onshore and offshore securities issues, China-related mergers & acquisitions and foreign investment. He is a Partner at Jingtian & Gongcheng and has been with the firm since 2003. Mr. Ren has been a Director of Beijing Dongcheng District State-owned Assets Administration Commission since January 2018. Mr. Ren obtained a Bachelor’s degree in Law and a Bachelor’s degree in Economics both from Peking University. He has been qualified to practice law in China.

Mr. Changqing YE has over 25 years of experience in professional accounting, financial advisory and investment. Mr. Ye obtained a Bachelor’s degree in Journalism from Huazhong University of Science and Technology in July 1992, and a Master’s degree in Business Administration from the University of Warwick in the United Kingdom in November 1999. Mr. Ye has been a Certified Public Accountant of the PRC since December 1994.

Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America’s best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biopharmaceutical industry. Dr. Sidransky is currently the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine’s Department of Otolaryngology; and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the Johns Hopkins University School of Medicine. Dr. Sidransky is also serving as a member on the Scientific Advisory Boards of numerous professional organizations and institutions, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI) of the U.S. Having authored over 550 peer-reviewed publications, contributed 45 cancer reviews and chapters, and invented 28 biotechnology patents, Dr. Sidransky is one of the world’s most highly cited researchers in clinical and medical journals.

Dr. Sidransky has accumulated immense industry experience and exceptional expertise, not only in scientific research, but also in business operations, corporate governance and investment strategies. Dr. Sidransky is a founder of a number of biotechnology companies such as Champions Oncology (Nasdaq; CSBR). Previously, Dr. Sidransky was Vice Chairman of ImClone Systems Inc., a global biopharmaceutical company committed to advancing oncology care, until its acquisition by Eli Lilly. Dr. Sidransky is also a Co-Founder and Managing Partner of the Israel Biotech Fund. Furthermore, Dr. Sidransky is a highly-experienced board member, after having served as a director on the boards of Galmed Pharmaceuticals (Nasdaq: GLMD), Orgenesis (Nasdaq: ORGS), Advaxis (Nasdaq: ADXS), and Ayala (Nasdaq: AYLA).

Mr. Changqing YE has over 25 years of experience in professional accounting, financial advisory and investment. Mr. Ye obtained a Bachelor’s degree in Journalism from Huazhong University of Science and Technology in July 1992, and a Master’s degree in Business Administration from the University of Warwick in the United Kingdom in November 1999. Mr. Ye has been a Certified Public Accountant of the PRC since December 1994.

Dr. Simon Dazhong LU, Ph.D., MBA, has more than 18 years of experience in the investment and consulting business. He is a Managing Director of SIDC Fund Management Company Ltd., a China-based private equity fund manager. From January 2008 to July 2009, Dr. Lu served as the Managing Director and a member of the investment committee of CEL Partners, a private equity firm. From September 2002 to December 2007, he was a partner of Shanghai Newmargin Ventures, a venture capital management company. Dr. Lu has also served as a securities analyst at China International Capital Corporation Limited, and as a financial analyst at Scotiabank in Toronto, Canada. Early in his career, he worked as an auditor and audit and business consulting supervisor at Arthur Andersen in Shanghai and Chicago. Dr. Lu graduated with a Bachelor of Economics from Nankai University, his Master of Business Administration from McGill University in Canada, and Ph.D. in Economics degree from Nankai University.

Mr. Wei REN has over 15 years of legal experience covering onshore and offshore securities issues, China-related mergers & acquisitions and foreign investment. He is a Partner at Jingtian & Gongcheng and has been with the firm since 2003. Mr. Ren has been a Director of Beijing Dongcheng District State-owned Assets Administration Commission since January 2018. Mr. Ren obtained a Bachelor’s degree in Law and a Bachelor’s degree in Economics both from Peking University. He has been qualified to practice law in China.

Mr. Wei REN has over 15 years of legal experience covering onshore and offshore securities issues, China-related mergers & acquisitions and foreign investment. He is a Partner at Jingtian & Gongcheng and has been with the firm since 2003. Mr. Ren has been a Director of Beijing Dongcheng District State-owned Assets Administration Commission since January 2018. Mr. Ren obtained a Bachelor’s degree in Law and a Bachelor’s degree in Economics both from Peking University. He has been qualified to practice law in China.

Dajun Yang, Ph.D., Chairman and CEO of Ascentage Pharma, has dedicated over 30 years to the research in oncology, the apoptotic pathway, as well as the R&D of innovative drugs. Since co-founding Ascentage Pharma in 2009, he made major breakthroughs in drug development and advanced multiple drug candidates with global first-/best-in-class potentials into clinical development in China, US, Australia and Europe. Under his leadership, olverembatinib, the first and only China-approved 3rd-generation BCR-ABL inhibitor, was launched and included into the NRDL, thus filling an urgent treatment gap in China.

Dr. Yang has led nearly 10 National Science & Technology Major Projects including the National High-tech R&D Program (863 Program) and “Major New Drug Development” projects. Being highly recognized for his work, Dr. Yang serves a range of positions outside his primary responsibilities, including professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center, deputy director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association, and part-time researcher in Pharmaceutical Innovations at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. In addition, Dr. Yang has served as the 8th president (2005-2006) of the Chinese Biopharmaceutical Association (CBA), USA. He and his team, widely respected in field of novel drug development, have received a series of high profile recognitions and prominent awards, including the Team for Major Innovations designations by both Suzhou municipality and Jiangsu province; the first ever Award for Teams Pioneering Innovations in Jiangsu province; the 2022 Team of Excellence in Science and Technology of Suzhou; the Tan Jiazhen Life Science Industrialization Award; Top 10 Business Leaders in the Pharmaceutical Industry, by the 14th Health China Forum organized by the People’s Daily; and the Dushu Lake Cup Award for Most Innovative Figure of Drug R&D.

Mr. Changqing YE has over 25 years of experience in professional accounting, financial advisory and investment. Mr. Ye obtained a Bachelor’s degree in Journalism from Huazhong University of Science and Technology in July 1992, and a Master’s degree in Business Administration from the University of Warwick in the United Kingdom in November 1999. Mr. Ye has been a Certified Public Accountant of the PRC since December 1994.

Dajun Yang, Ph.D., Chairman and CEO of Ascentage Pharma, has dedicated over 30 years to the research in oncology, the apoptotic pathway, as well as the R&D of innovative drugs. Since co-founding Ascentage Pharma in 2009, he made major breakthroughs in drug development and advanced multiple drug candidates with global first-/best-in-class potentials into clinical development in China, US, Australia and Europe. Under his leadership, olverembatinib, the first and only China-approved 3rd-generation BCR-ABL inhibitor, was launched and included into the NRDL, thus filling an urgent treatment gap in China.

Dr. Yang has led nearly 10 National Science & Technology Major Projects including the National High-tech R&D Program (863 Program) and “Major New Drug Development” projects. Being highly recognized for his work, Dr. Yang serves a range of positions outside his primary responsibilities, including professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center, deputy director of the Drug R&D Specialty Committee of China Pharmaceutical Innovation and Research Development Association, and part-time researcher in Pharmaceutical Innovations at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. In addition, Dr. Yang has served as the 8th president (2005-2006) of the Chinese Biopharmaceutical Association (CBA), USA. He and his team, widely respected in field of novel drug development, have received a series of high profile recognitions and prominent awards, including the Team for Major Innovations designations by both Suzhou municipality and Jiangsu province; the first ever Award for Teams Pioneering Innovations in Jiangsu province; the 2022 Team of Excellence in Science and Technology of Suzhou; the Tan Jiazhen Life Science Industrialization Award; Top 10 Business Leaders in the Pharmaceutical Industry, by the 14th Health China Forum organized by the People’s Daily; and the Dushu Lake Cup Award for Most Innovative Figure of Drug R&D.

Mr. Wei REN has over 15 years of legal experience covering onshore and offshore securities issues, China-related mergers & acquisitions and foreign investment. He is a Partner at Jingtian & Gongcheng and has been with the firm since 2003. Mr. Ren has been a Director of Beijing Dongcheng District State-owned Assets Administration Commission since January 2018. Mr. Ren obtained a Bachelor’s degree in Law and a Bachelor’s degree in Economics both from Peking University. He has been qualified to practice law in China.

Known for in research in biomarkers for early detection and therapy and profiled by TIME magazine in 2001 as one of America’s best in science and medicine, Dr. Sidransky is a leading expert in oncology and precision medicine widely respected in the biopharmaceutical industry. Dr. Sidransky is currently the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine’s Department of Otolaryngology; and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the Johns Hopkins University School of Medicine. Dr. Sidransky is also serving as a member on the Scientific Advisory Boards of numerous professional organizations and institutions, including the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI) of the U.S. Having authored over 550 peer-reviewed publications, contributed 45 cancer reviews and chapters, and invented 28 biotechnology patents, Dr. Sidransky is one of the world’s most highly cited researchers in clinical and medical journals.

Dr. Sidransky has accumulated immense industry experience and exceptional expertise, not only in scientific research, but also in business operations, corporate governance and investment strategies. Dr. Sidransky is a founder of a number of biotechnology companies such as Champions Oncology (Nasdaq; CSBR). Previously, Dr. Sidransky was Vice Chairman of ImClone Systems Inc., a global biopharmaceutical company committed to advancing oncology care, until its acquisition by Eli Lilly. Dr. Sidransky is also a Co-Founder and Managing Partner of the Israel Biotech Fund. Furthermore, Dr. Sidransky is a highly-experienced board member, after having served as a director on the boards of Galmed Pharmaceuticals (Nasdaq: GLMD), Orgenesis (Nasdaq: ORGS), Advaxis (Nasdaq: ADXS), and Ayala (Nasdaq: AYLA).